The findings agree with preclinical evidence and provide the first, albeit still preliminary in vivo evidence suggesting a role for brain cannabinoid type 1 (CB1) receptors in alcohol dependence (AD). The current study design does not answer the important question of whether elevated CB1 receptors are a preexisting vulnerability factor for AD or whether elevations develop as a consequence of AD.